“10,000 pages of PIP docs and more than a dozen on-site audits” exonerates TÜV, claims the NB
This article was originally published in Clinica
Executive Summary
TÜV Rheinland, the notified body challenging a class action over its role in relation to the EU marketing of fraudulent PIP breast implants, has reiterated its dismissal of allegations that it failed in its responsibilities, as brought to court by French lawyer Laurent Gaudon.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.